Exelixis, Inc.
Exelixis, Inc., a prominent biotechnology firm headquartered in the United States, has established itself as a leader in the oncology sector since its founding in 1994. With a focus on developing innovative cancer therapies, Exelixis operates primarily in North America and has made significant strides in advancing targeted treatments for various malignancies. The company’s flagship product, cabozantinib, exemplifies its commitment to precision medicine, offering unique mechanisms of action that address complex tumour biology. Exelixis has achieved notable milestones, including successful clinical trials and strategic partnerships, solidifying its position in the competitive biopharmaceutical landscape. With a robust pipeline and a dedication to improving patient outcomes, Exelixis continues to be a key player in the fight against cancer.
DitchCarbon Score
How does Exelixis, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Exelixis, Inc.'s score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Exelixis, Inc.'s reported carbon emissions
Exelixis, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi). As there is no emissions data available, it is important to note that Exelixis, Inc. has not cascaded any climate-related targets or data from a parent or related organisation. This lack of information suggests that the company may still be in the early stages of developing its climate strategy or reporting framework. In the context of the biotechnology industry, where Exelixis operates, there is an increasing emphasis on sustainability and carbon footprint reduction. Companies are encouraged to adopt transparent reporting practices and set ambitious targets to align with global climate goals. However, without specific commitments or data, Exelixis, Inc. remains unaccounted for in the broader conversation on corporate climate responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Exelixis, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
